ArticleScientific reports2019
Staurosporine from Streptomyces sanyensis activates Programmed Cell Death in Acanthamoeba via the mitochondrial pathway and presents low in vitro cytotoxicity levels in a macrophage cell line.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Alternative splicing drives a dynamic transcriptomic response duringMicrobial cell (Graz, Austria) · 2025Article
- Staurosporine as a Potential Treatment forMarine drugs · 2024Article
- Cell Death ofPathogens (Basel, Switzerland) · 2024Article
- Amoebicidal effect of synthetic indoles againstAntimicrobial agents and chemotherapy · 2024Article
- The In Vitro Anti-Parasitic Activities of Emodin towardPharmaceuticals (Basel, Switzerland) · 2023Article
- Promising Antiparasitic Natural and Synthetic Products from Marine Invertebrates and Microorganisms.Marine drugs · 2023Review
- Article
- Energetic metabolic reprogramming in Jurkat DFF40-deficient cancer cells.Molecular and cellular biochemistry · 2022Article
- Indispensable role of microbes in anticancer drugs and discovery trends.Applied microbiology and biotechnology · 2022Review
- Opportunistic free-living amoebal pathogens.Pathogens and global health · 2022Article
- High oxygen concentrations inhibit Acanthamoeba spp.Parasitology research · 2021Article
- In vitro evaluation of commercial foam Belcils® on Acanthamoeba spp.International journal for parasitology. Drugs and drug resistance · 2020Article
- Evaluation of Indolocarbazoles fromMicroorganisms · 2020Article
- Antikinetoplastid Activity of Indolocarbazoles fromBiomolecules · 2020Article
- Antiamoebic Activities of Indolocarbazole Metabolites Isolated fromMarine drugs · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the search for novel therapeutic agents against Acanthamoeba species has been focused on the evaluation of natural resources. Among them, marine microorganisms have risen as a source of bioactive compounds with the advantage of the ability to obtain unlimited and constant amounts of the compounds in contrast to other natural sources such as plants. Furthermore, marine actinomycetes have recently been reported as highly rich in bioactive agents including salinosporamides, xiamycines, indolocarbazoles, naphtyridines, phenols, dilactones such as antimycines and macrolides among others. In this study, staurosporine (STS) was isolated from a strain of Streptomyces sanyensis and tested against Acanthamoeba to characterize the therapeutic potential of STS against this protozoan parasite. We have established that STS is active against both stages of the Acanthamoeba life cycle, by the activation of Programmed Cell Death via the mitochondrial pathway of the trophozoite. We have also established that STS has relatively low toxicity towards a macrophage cell line. However, previous studies have highlighted higher toxicity levels induced on other vertebrate cell lines and future research to lower these toxicity issues should be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.